Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 27th February 2017
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Komodo dragon blood could help in AMR fight
komodo dragon
Komodo dragon saliva contains at least 57 species of bacteria that are thought to help kill their prey, but the Komodo itself appears to be resistant to the bacteria.
Scientists identify antimicrobial activity in lizard’s blood

Antimicrobial substances discovered in the blood of Komodo dragons could help with the development of new drugs for treating antibiotic resistant infections, scientists say.

A study published in the Journal of Proteome Research describes antimicrobial protein fragments that appear to help the lizards resist deadly infections.

Komodo dragon saliva contains at least 57 species of bacteria that are thought to help kill their prey, but the Komodo itself appears to be resistant to the bacteria.

Researchers from the College of Science at George Mason University identified and sequenced 48 potential cationic antimicrobial peptides (CAMPs) - an essential part of the innate immune system - in the blood of Komodo dragons. All but one of these were derived from histone proteins, which are known to have antimicrobial activities.

Eight were synthesised and tested against Pseudomonas aeruginosa and Staphylococcus aureus. Seven out of eight showed significant potency against both bacteria and the eighth was only effective against P. aeruginosa. The researchers conclude that Komodo blood plasma contains a host of potentially viable antimicrobial peptides that could lead to new treatments.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.